Pierre Fabre licenses cancer antibody to Abbott

Friday 5 February 2010

Privately-owed French pharmaceutical company, Pierre Fabre SA, has licensed exclusive rights to Abbott Laboratories to a preclinical monoclonal antibody for cancer that targets a membrane receptor known as c-Met.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France